BioNTech SE (22UA.F)

EUR 107.0

(-2.28%)

EBITDA Summary of BioNTech SE

BioNTech SE's latest annual EBITDA in 2023 was 1.08 Billion EUR , down -91.18% from previous year.
BioNTech SE's latest quarterly EBITDA in 2024 Q2 was -652.88 Million EUR , down -159.0% from previous quarter.
BioNTech SE reported an annual EBITDA of 12.85 Billion EUR in 2022, down -12.52% from previous year.
BioNTech SE reported an annual EBITDA of 15.73 Billion EUR in 2021, up 35652.26% from previous year.
BioNTech SE reported a quarterly EBITDA of -476.08 Million EUR for 2024 Q1, down -139.16% from previous quarter.
BioNTech SE reported a quarterly EBITDA of -379 Million EUR for 2023 Q2, down -145.09% from previous quarter.

Annual EBITDA Chart of BioNTech SE (2023 - 2017)

Historical Annual EBITDA of BioNTech SE (2023 - 2017)

Year	EBITDA	EBITDA Growth
2023	1.08 Billion EUR	-91.18%
2022	12.85 Billion EUR	-12.52%
2021	15.73 Billion EUR	35652.26%
2020	-97.89 Million EUR	71.19%
2019	-143.4 Million EUR	-387.11%
2018	-24.63 Million EUR	38.44%
2017	-70.13 Million EUR	0.0%

Year	EBITDA	EBITDA Growth
2024 Q2	-652.88 Million EUR	-159.0%
2024 Q1	-476.08 Million EUR	-139.16%
2023 Q2	-379 Million EUR	-145.09%
2023 Q4	507.4 Million EUR	135.23%
2023 FY	- EUR	-91.18%
2023 Q3	215.7 Million EUR	156.91%
2023 Q1	840.6 Million EUR	-74.99%
2022 Q4	3.36 Billion EUR	48.56%
2022 Q2	1.95 Billion EUR	-58.54%
2022 Q1	4.72 Billion EUR	2.98%
2022 FY	- EUR	-12.52%
2022 Q3	2.26 Billion EUR	15.6%
2021 Q3	4.57 Billion EUR	9.63%
2021 Q1	1.63 Billion EUR	740.19%
2021 Q2	4.17 Billion EUR	155.84%
2021 FY	- EUR	35652.26%
2021 Q4	4.58 Billion EUR	0.14%
2020 FY	- EUR	71.19%
2020 Q4	194.27 Million EUR	209.69%
2020 Q3	-177.1 Million EUR	-146.2%
2020 Q2	-71.93 Million EUR	-62.51%
2020 Q1	-44.26 Million EUR	8.74%
2019 Q1	-33.07 Million EUR	-560.55%
2019 Q3	-21.08 Million EUR	45.97%
2019 Q4	-48.5 Million EUR	-130.03%
2019 FY	- EUR	-387.11%
2019 Q2	-39.03 Million EUR	-18.02%
2018 Q2	-10.52 Million EUR	0.0%
2018 Q1	-10.52 Million EUR	0.0%
2018 Q3	-16.3 Million EUR	-54.85%
2018 Q4	7.18 Million EUR	144.05%
2018 FY	- EUR	38.44%
2017 FY	- EUR	0.0%

Peer EBITDA Comparison of BioNTech SE

Name	EBITDA	EBITDA Difference
CureVac N.V.	-234.09 Million EUR	564.608%
Biotest Aktiengesellschaft	179 Million EUR	-507.598%
Biotest Aktiengesellschaft	179 Million EUR	-507.598%
BRAIN Biotech AG	-2.38 Million EUR	45663.469%
Formycon AG	81.05 Million EUR	-1241.838%
Heidelberg Pharma AG	-18.7 Million EUR	5914.06%
Medigene AG	-14.58 Million EUR	7556.977%